CLINICAL TRIALS PROFILE FOR DASIGLUCAGON HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for dasiglucagon hydrochloride
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02916251 ↗ | ZP4207(Dasiglucagon) Administered to T1D Patients to Assess the PK and PD Compared to Marketed Glucagon | Completed | Zealand Pharma | Phase 2 | 2016-12-01 | The trial is a single-centre, randomised, sequential, cross-over trial assessing pharmacokinetic and pharmacodynamic responses after micro-doses of ZP4207 (dasiglucagon*) administered subcutaneously to patients with type 1 diabetes mellitus under euglycaemic and hypoglycaemic conditions and compared to marketed glucagon. *dasiglucagon is the proposed International Nonproprietary Name (pINN) for ZP4207 |
| NCT02971228 ↗ | Feasibility Trial Testing the Bionic Pancreas With ZP4207 | Completed | Beta Bionics, Inc. | Phase 2 | 2016-11-01 | The purpose of this study was to determine whether the Bionic Pancreas with ZP4207 (dasiglucagon*) was feasible to improve glycemic control in adults with type 1 diabetes mellitus. *dasiglucagon is the proposed International Nonproprietary Name (pINN) for ZP4207 |
| NCT02971228 ↗ | Feasibility Trial Testing the Bionic Pancreas With ZP4207 | Completed | Massachusetts General Hospital | Phase 2 | 2016-11-01 | The purpose of this study was to determine whether the Bionic Pancreas with ZP4207 (dasiglucagon*) was feasible to improve glycemic control in adults with type 1 diabetes mellitus. *dasiglucagon is the proposed International Nonproprietary Name (pINN) for ZP4207 |
| NCT02971228 ↗ | Feasibility Trial Testing the Bionic Pancreas With ZP4207 | Completed | Zealand Pharma | Phase 2 | 2016-11-01 | The purpose of this study was to determine whether the Bionic Pancreas with ZP4207 (dasiglucagon*) was feasible to improve glycemic control in adults with type 1 diabetes mellitus. *dasiglucagon is the proposed International Nonproprietary Name (pINN) for ZP4207 |
| NCT03216226 ↗ | A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes Mellitus | Completed | SynteractHCR | Phase 3 | 2017-06-28 | The trial's objective is to evaluate the immunogenicity of repeated single doses of dasiglucagon* and GlucaGen following subcutaneous (SC) administration in patients with type 1 diabetes mellitus (T1DM) and further to evaluate the safety and tolerability of dasiglucagon and GlucaGen. *dasiglucagon is the proposed International Nonproprietary Name (pINN) for ZP4207 |
| NCT03216226 ↗ | A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes Mellitus | Completed | Zealand Pharma | Phase 3 | 2017-06-28 | The trial's objective is to evaluate the immunogenicity of repeated single doses of dasiglucagon* and GlucaGen following subcutaneous (SC) administration in patients with type 1 diabetes mellitus (T1DM) and further to evaluate the safety and tolerability of dasiglucagon and GlucaGen. *dasiglucagon is the proposed International Nonproprietary Name (pINN) for ZP4207 |
| NCT03378635 ↗ | A Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Type 1 Diabetes Subjects | Completed | Zealand Pharma | Phase 3 | 2017-12-07 | The objective of the trial is to demonstrate superiority of dasiglucagon compared to placebo following a single subcutaneous dose administered to subjects with type 1 diabetes mellitus (T1DM) with insulin-induced hypoglycemia. Additionally to compare the glycemic response observed after administration dasiglucagon with that of GlucaGen®. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for dasiglucagon hydrochloride
Condition Name
Clinical Trial Locations for dasiglucagon hydrochloride
Trials by Country
Clinical Trial Progress for dasiglucagon hydrochloride
Clinical Trial Phase
Clinical Trial Sponsors for dasiglucagon hydrochloride
Sponsor Name
